ReviewViruses2022
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- HBV RNA Predicts the Risk of Off-Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Hepatitis surface B antigen clearance induced by long-term tenofovir disoproxil fumarate monotherapy in chronic hepatitis B treatment: a meta-analysis and longitudinal modeling analysis.Virology journal · 2025Pooled it
- Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis.Frontiers in public health · 2022Pooled it
- Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B.Nature biomedical engineering · 2026Article
- A Multi-Model Strategy for Optimizing Hepatitis B Virus preS1 Epitope Recognition by the Antibody HzKR127.Current issues in molecular biology · 2026Article
- A Novel Host-Based Immunotherapy for the Suppression of HBV and HCV Replication: Heat-KilledCells · 2026Article
- A Review of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection in Botswana.Viruses · 2026Review
- Review
- Kaempferol inhibits hepatitis B virus replicationFrontiers in cellular and infection microbiology · 2026Article
- Interferon therapy-induced reduction in PD-1 + CD8 + and CD160 + CD8 + T cells is associated with functional cure in hepatitis B.BMC infectious diseases · 2025Article
- An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection.Nature communications · 2025Article
- Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing.Diagnostics (Basel, Switzerland) · 2025Review
- Association between hepatitis B virus markers and liver fibrosis staging in patients with chronic hepatitis B.World journal of gastrointestinal surgery · 2025Article
- HBsAg loss in HIV/HBV coinfected patients: Hepatitis B cure insights and implications.Infectious diseases & immunity · 2025Review
- Cumulative Hepatitis B Surface Antigen/Hepatitis B Virus DNA Ratio in Immune-tolerant Hepatitis B Patients: A 10-year Follow-up Study.Journal of clinical and translational hepatology · 2025Article
- Performance Evaluation of a HBsAg-Specific Immunoadsorbent Based on a Humanized Anti-HBsAg Monoclonal Antibody.Biomedicines · 2025Article
- Global trends and insights in interferon therapy for chronic hepatitis B: a bibliometric analysis.Virology journal · 2025Article
- Evaluation of HBsAg and HBeAg seroconversion rates in patients diagnosed with chronic hepatitis B: A 10-year retrospective analysis.Saudi medical journal · 2025Article
- [Research progress on predictive indicators of a clinical cure for chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Hepatitis B virus surface antigen drives T cell immunity through non-canonical antigen presentation in mice.Nature communications · 2025Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the availability of effective vaccines and antiviral therapy over the past two to three decades, chronic hepatitis B virus (HBV) infection remains a major global health threat as a leading cause of cirrhosis and liver cancer. Functional HBV cure defined as hepatitis B surface antigen (HBsAg) loss and undetectable serum HBV DNA is associated with improved clinical outcomes in patients with chronic HBV infection. However, spontaneous loss of HBsAg is rare and occurs in only 1% of all HBsAg-positive individuals annually. Furthermore, the rate of functional cure with currently available antiviral therapy is even lower, <1% patients on treatment per year. Nonetheless, HBsAg loss has become the new target or therapeutic endpoint for antiviral treatment. Recently, there has been much excitement surrounding the development of novel antiviral agents such as small interfering RNA (siRNA), core assembly modulators (CAMs), nucleic acid polymers (NAPs) among others, which may be used in combination with nucleos(t)ide analogs and possibly immunomodulatory therapies to achieve functional cure in a significant proportion of patients with chronic hepatitis B. Novel assays with improved sensitivity for detection of very low levels of HBsAg and to determine the source of HBsAg production will also be required to measure efficacy of newer antiviral treatments for HBV cure. In this narrative review, we will define HBV cure, discuss various sources of HBsAg production, evaluate rates of HBsAg loss with current and future antiviral agents, review clinical factors associated with spontaneous HBsAg loss, and explore clinical implications of functional cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.